全文获取类型
收费全文 | 180024篇 |
免费 | 16095篇 |
国内免费 | 7239篇 |
专业分类
耳鼻咽喉 | 2481篇 |
儿科学 | 4198篇 |
妇产科学 | 2022篇 |
基础医学 | 31496篇 |
口腔科学 | 5357篇 |
临床医学 | 13833篇 |
内科学 | 23389篇 |
皮肤病学 | 5741篇 |
神经病学 | 10186篇 |
特种医学 | 4289篇 |
外国民族医学 | 119篇 |
外科学 | 15495篇 |
综合类 | 27702篇 |
一般理论 | 1篇 |
预防医学 | 5879篇 |
眼科学 | 3696篇 |
药学 | 14952篇 |
53篇 | |
中国医学 | 5856篇 |
肿瘤学 | 26613篇 |
出版年
2024年 | 63篇 |
2023年 | 2568篇 |
2022年 | 3175篇 |
2021年 | 5624篇 |
2020年 | 6284篇 |
2019年 | 7040篇 |
2018年 | 5527篇 |
2017年 | 6015篇 |
2016年 | 6190篇 |
2015年 | 6794篇 |
2014年 | 10440篇 |
2013年 | 11745篇 |
2012年 | 10220篇 |
2011年 | 11568篇 |
2010年 | 9603篇 |
2009年 | 9157篇 |
2008年 | 9640篇 |
2007年 | 9846篇 |
2006年 | 8994篇 |
2005年 | 8238篇 |
2004年 | 7309篇 |
2003年 | 6354篇 |
2002年 | 5164篇 |
2001年 | 4462篇 |
2000年 | 3657篇 |
1999年 | 3165篇 |
1998年 | 2590篇 |
1997年 | 2523篇 |
1996年 | 2198篇 |
1995年 | 2218篇 |
1994年 | 1980篇 |
1993年 | 1650篇 |
1992年 | 1364篇 |
1991年 | 1285篇 |
1990年 | 995篇 |
1989年 | 949篇 |
1988年 | 892篇 |
1987年 | 705篇 |
1986年 | 649篇 |
1985年 | 851篇 |
1984年 | 749篇 |
1983年 | 543篇 |
1982年 | 558篇 |
1981年 | 458篇 |
1980年 | 382篇 |
1979年 | 291篇 |
1978年 | 200篇 |
1977年 | 159篇 |
1976年 | 116篇 |
1973年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
1.
2.
Adam H. Fox MD MS Mizuki Nishino MD Raymond U. Osarogiagbon MBBS M. Patricia Rivera MD Lauren S. Rosenthal MPH Robert A. Smith PhD Farhood Farjah MD Lynette M. Sholl MD Gerard A. Silvestri MD MS Bruce E. Johnson MD 《CA: a cancer journal for clinicians》2023,73(4):358-375
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios. 相似文献
3.
4.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
5.
6.
7.
8.
Mandy van Gulijk Bob Belderbos Daphne Dumoulin Robin Cornelissen Koen Bezemer Larissa Klaase Floris Dammeijer Joachim Aerts 《International journal of cancer. Journal international du cancer》2023,152(7):1438-1443
Immunotherapy with anti-PD1/PD-L1 is effective in only a subgroup of patients with malignant pleural mesothelioma (MPM). We investigated the efficacy of a combination of anti-PD1/PD-L1 and dendritic cell (DC) therapy to optimally induce effective anti-tumor immunity in MPM in both humans and mice. Data of nine MPM patients treated with DC therapy and sequential anti-PD1 treatment were collected and analyzed for progression-free survival (PFS) and overall survival (OS). Survival and T-cell responses were monitored in AC29 mesothelioma-bearing mice treated concurrently with the combination therapy; additionally, the role of the tumor-draining lymph node (TDLN) was investigated. The combination therapy resulted in a median OS and PFS of 17.7 and 8.0 months, respectively. Grade 3 to 4 treatment-related adverse events had not been reported. Survival of the mesothelioma-bearing mice treated with the combination therapy was longer than that of untreated mice, and coincided with improved T-cell activation in peripheral blood and less T-cell exhaustion in end stage tumors. Comparable results were obtained when solely the TDLN was targeted. We concluded that this combination therapy is safe and shows promising OS and PFS. The murine data support that PD-L1 treatment may reinvigorate the T-cell responses induced by DC therapy, which may primarily be the result of TDLN targeting. 相似文献
9.
Ali Soroush Reza Malekzadeh Gholamreza Roshandel Masoud Khoshnia Hossein Poustchi Farin Kamangar Paul Brennan Paolo Boffetta Sanford M. Dawsey Christian C. Abnet Julian A. Abrams Arash Etemadi 《International journal of cancer. Journal international du cancer》2023,152(6):1137-1149
Prior studies have conflicting findings regarding the association between gastroesophageal reflux disease (GERD) and esophageal squamous cell carcinoma (ESCC). We examined this relationship in a prospective cohort in a region of high ESCC incidence. Baseline exposure data were collected from 50 045 individuals using in-person interviews at the time of cohort entry. Participants were followed until they developed cancer, died, or were lost to follow up. Participants with GERD symptoms were categorized into any GERD (heartburn or regurgitation), mixed symptoms, or heartburn alone. Multivariable Cox regression was used to assess the relationship between GERD symptom group and histologically confirmed ESCC. The model was adjusted for known risk factors for GERD and ESCC. 49 559 individuals were included in this study, of which 9005 had GERD symptoms. Over 13.0 years of median follow up, 290 individuals were diagnosed with ESCC. We found no association between any GERD and risk of ESCC (aHR 0.90, 95% CI: 0.66-1.24, P = .54). Similar findings were observed for the GERD symptom subtypes. Significant interactions between any GERD and sex (P = .013) as well as tobacco smoking (P = .028) were observed. In post-hoc analyses, GERD was associated with a decreased risk of ESCC in men (aHR 0.51, 95% CI: 0.27-0.98 P = .04) and in smokers (aHR 0.26, 95% CI: 0.08-0.83 P = .02). While there was little evidence for an overall association between GERD symptoms and ESCC risk, significant interactions with sex and smoking were observed. Men and smokers with GERD symptoms had a lower risk of ESCC development. 相似文献
10.
Xi Tian Yue Wang Wenhao Xu Haidan Tang Shuxuan Zhu Aihetaimujiang Anwaier Wangrui Liu Wenfeng Wang Wenkai Zhu Jiaqi Su Yuanyuan Qu Hailiang Zhang Dingwei Ye 《International journal of cancer. Journal international du cancer》2023,152(1):66-78
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab. 相似文献